CN100349888C - 药物化合物 - Google Patents

药物化合物 Download PDF

Info

Publication number
CN100349888C
CN100349888C CNB038159295A CN03815929A CN100349888C CN 100349888 C CN100349888 C CN 100349888C CN B038159295 A CNB038159295 A CN B038159295A CN 03815929 A CN03815929 A CN 03815929A CN 100349888 C CN100349888 C CN 100349888C
Authority
CN
China
Prior art keywords
hydrate
acid
compound
quinoline
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038159295A
Other languages
English (en)
Chinese (zh)
Other versions
CN1665806A (zh
Inventor
D·F·海曼
M·赖特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenova Ltd
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Ltd filed Critical Xenova Ltd
Publication of CN1665806A publication Critical patent/CN1665806A/zh
Application granted granted Critical
Publication of CN100349888C publication Critical patent/CN100349888C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB038159295A 2002-05-14 2003-05-13 药物化合物 Expired - Fee Related CN100349888C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37975902P 2002-05-14 2002-05-14
US60/379,759 2002-05-14

Publications (2)

Publication Number Publication Date
CN1665806A CN1665806A (zh) 2005-09-07
CN100349888C true CN100349888C (zh) 2007-11-21

Family

ID=29420557

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038159295A Expired - Fee Related CN100349888C (zh) 2002-05-14 2003-05-13 药物化合物

Country Status (11)

Country Link
US (1) US7524861B2 (https=)
EP (1) EP1506188B1 (https=)
JP (1) JP4464814B2 (https=)
KR (1) KR101060971B1 (https=)
CN (1) CN100349888C (https=)
AT (1) ATE423778T1 (https=)
AU (1) AU2003233899B2 (https=)
BR (1) BR0309990A (https=)
CA (1) CA2485430C (https=)
DE (1) DE60326341D1 (https=)
WO (1) WO2003095447A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
RS56037B1 (sr) 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
EP1979367A2 (en) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 薬学的組成物およびその投与
CA2919522C (en) 2013-07-30 2019-02-26 Gilead Connecticut, Inc. Formulation of syk inhibitors
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
CN103804352B (zh) * 2014-01-23 2017-06-13 中国药科大学 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
CN104327046B (zh) * 2014-10-14 2017-11-17 中国药科大学 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用
CN104434947B (zh) * 2014-11-07 2016-11-09 滨州医学院附属医院 一种抗胆管癌的药物组合物及其应用
EP3378858A1 (en) * 2017-03-21 2018-09-26 Bioprojet Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same
CA3073871A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. Polymorphs of syk inhibitors
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
WO2022076662A1 (en) * 2020-10-07 2022-04-14 Athenex, Inc. Acetamido-phenylbenzamide derivatives and methods of using the same
CN112724124A (zh) * 2021-01-18 2021-04-30 林剑雄 4-羟基喹啉类衍生物及其制备方法和在抗肿瘤药物中的应用
CN117304105A (zh) * 2023-08-18 2023-12-29 中国科学院基础医学与肿瘤研究所(筹) 一种靶向抑制ABCB1(P-gp)的化合物及制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241181A (zh) * 1996-10-18 2000-01-12 埃克森诺瓦有限公司 药用化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK280864B6 (en) * 1991-01-11 2000-08-14 Laboratoires Glaxo Sa Acridine derivatives, process for their preparation, and pharmaceutical compositions based thereon
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241181A (zh) * 1996-10-18 2000-01-12 埃克森诺瓦有限公司 药用化合物

Also Published As

Publication number Publication date
WO2003095447A1 (en) 2003-11-20
US20050222199A1 (en) 2005-10-06
EP1506188A1 (en) 2005-02-16
US7524861B2 (en) 2009-04-28
AU2003233899B2 (en) 2009-03-12
JP4464814B2 (ja) 2010-05-19
CN1665806A (zh) 2005-09-07
DE60326341D1 (de) 2009-04-09
EP1506188B1 (en) 2009-02-25
JP2005538051A (ja) 2005-12-15
AU2003233899A1 (en) 2003-11-11
KR20050009706A (ko) 2005-01-25
KR101060971B1 (ko) 2011-09-01
BR0309990A (pt) 2005-02-22
CA2485430A1 (en) 2003-11-20
ATE423778T1 (de) 2009-03-15
CA2485430C (en) 2011-12-06

Similar Documents

Publication Publication Date Title
CN100349888C (zh) 药物化合物
CN108366994B (zh) 新型Jak1选择性抑制剂及其用途
CN108601781B (zh) 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用
CN114409653A (zh) 一种桥环并嘧啶并环类化合物及其用途
EA022341B1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EP2903979B1 (en) Novel compounds, their preparation and their uses
CA2753135A1 (fr) Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique
JP2013526562A (ja) 新規ピリミジン誘導体
KR20230031321A (ko) 치환된 페닐 또는 피리디닐 모이어티를 갖는 serd 트리시클릭 화합물의 제조 방법
RU2163599C2 (ru) Таксаны, способ их получения и лекарственный препарат на их основе
WO2018191642A1 (en) Novel amodiaquine analogs and methods of uses thereof
DK2610257T3 (en) DI-IMIDED DERIVATIVE OF BERBAMINE AND METHOD FOR PREPARING AND USING THEREOF
KR20150105302A (ko) 헤지 호그 신호 경로의 억제제로서 환상 술폰아미드 함유 유도체
US10471154B2 (en) Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
CN1181062C (zh) 2-苯氧基嘧啶衍生物及其治疗用途
CN1273452C (zh) 7-(4,4-二甲基-3-氨甲基吡咯烷-1-基)取代的新喹啉羧酸衍生物及其制法
CN114616229B (zh) 三环化合物及其药物用途
CN102712655B (zh) 小檗胺的二酰亚胺化衍生物、其制备方法和应用
EP4605086A1 (en) Treatment of leishmaniasis
CA2886744C (en) Imatinib derivatives, their preparation and use to treat cancer and bacterial and viral infections
CN1467210A (zh) 20-位酯化的喜树碱衍生物及其制法和其药物组合物与用途
HK1257988B (en) 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071121

Termination date: 20140513